Success of Amarin trial could jumpstart further omega 3s research.

The recent success of an omega 3 drug trial should help to reinvigorate research into these ingredients’ effects, especially at
higher dosages, said one of the field’s prominent experts.William S. Harris, PhD of the Sanford School of Medicine at the University south Kakota , said, the recently reported results of the REDUCE-IT trial conducted by Amarin on its Vascepa drug （which is almost pure EPA) could open up a new era of high dose trials for omega-3s. The trial showed an approximately 25%, reduction in the risk of major adverse cardiovascular events(a composite of cardiovascular death, nonfatal myocardial infarctionk nonfatal strokek coronary revascularizationk or unstable angina requiring hospitalization) in at risk patients after statin therapy.